Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

NCT03206463 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Feasibility pilot was completed

Conditions

Delta-9-Tetrahydroncannabinol
Bipolar Disorder
Healthy Controls

Interventions

DRUG: 4 mg Delta-9-THC
DRUG: Placebo
DRUG: 2 mg Delta-9-THC

Sponsor

Yale University